Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome

被引：4
|
作者：
Yanada, Masamitsu [1 ]
Huang, Xuelin
Garcia-Manero, Guillermo
O'Brien, Susan
Ravandi, Farhad
Borthakur, Gautam
Faderl, Stefan
Issa, Jean-Pierre
Kantarjian, Hagop
Estey, Elihu
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukimia, Houston, TX 77025 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biostatr, Houston, TX 77025 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2007年 / 138卷 / 04期
关键词：
acute myeloid leukaemia; myelodysplastic syndrome; targeted therapy; haematological improvement; survival;
D O I：
10.1111/j.1365-2141.2007.06670.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：555 / 557
页数：3
相关论文
共 50 条
  • [1] Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS)
    Yanada, M.
    Huang, X.
    O'Brien, S.
    Garcia-Manero, G.
    Ravandi, F.
    Borthakur, G.
    Issa, J.
    Giles, F.
    Kantarjian, H.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism
    Buckstein, Rena
    LANCET HAEMATOLOGY, 2015, 2 (10): : E396 - E397
  • [3] Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
    Niessen, F. A.
    van Mourik, M. S. M.
    Bruns, A. H. W.
    Raijmakers, R. A. P.
    de Groot, M. C. H.
    van der Bruggen, T.
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2020, 9 (01)
  • [4] Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
    F. A. Niessen
    M. S. M. van Mourik
    A. H. W. Bruns
    R. A. P. Raijmakers
    M. C. H. de Groot
    T. van der Bruggen
    Antimicrobial Resistance & Infection Control, 9
  • [5] Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia
    Zhang, Xi
    LANCET HAEMATOLOGY, 2023, 10 (03): : E159 - E160
  • [6] Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia
    Wei, Andrew
    Tan, Peter
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 675 - 676
  • [7] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
    Stringer, R.
    Rider, D. T.
    Newman, D. J.
    Grace, D. R.
    HAEMATOLOGICA, 2015, 100 : 725 - 726
  • [8] Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome
    Rebecca van Grootveld
    Valentina Masarotto
    Peter A. von dem Borne
    Nicole M. A. Blijlevens
    Dana A. Chitu
    Martha T. van der Beek
    Marta Fiocco
    Mark G. J. de Boer
    BMC Infectious Diseases, 23
  • [9] Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome
    van Grootveld, Rebecca
    Masarotto, Valentina
    von dem Borne, Peter A.
    Blijlevens, Nicole M. A.
    Chitu, Dana A.
    van der Beek, Martha T.
    Fiocco, Marta
    de Boer, Mark G. J.
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [10] Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia
    Oosterveld, M
    de Witte, T
    BLOOD REVIEWS, 2000, 14 (04) : 182 - 189
12345